June 2, 2020 / 5:06 AM / a month ago

BRIEF-Bergenbio: First Covid19 Patient Dosed With Bemcentinib In Accord Trial

June 2 (Reuters) - Bergenbio ASA:

* BERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL

* STUDY IS FULLY FUNDED BY DHSC AND UKRI AND IS BEING MANAGED BY CLINICAL RESEARCH COMPANY IQVIA. DRUG MATERIAL AND OTHER TRIAL RESOURCES WILL BE PROVIDED BY BERGENBIO

* ANTICIPATES THAT TOP LINE DATA WILL READOUT LATER IN SUMMER Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below